GIM
SLNO

Glenmede Investment Management’s Soleno Therapeutics SLNO Stock Holding History

Glenmede Investment Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$436K Buy
6,448
+1,095
+20% +$81.2K ﹤0.01% 981
2025
Q2 		$448K Buy
+5,353
New +$401K ﹤0.01% 961

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Glenmede Investment Management's SLNO Position: Q3 2025 in Review

Glenmede Investment Management increased its Soleno Therapeutics (SLNO) stake by 20% in Q3 2025, buying an estimated $81.2K and bringing the position to 6,448 shares worth $436K. The position accounts for ﹤0.01% of the portfolio, ranked #981.

Glenmede Investment Management first reported a position in SLNO in Q2 2025 and has held it in 2 quarters since. The position peaked at $448K in Q2 2025. 240 funds tracked by Wall St. Rank hold SLNO as of Q3 2025.

  • Glenmede Investment Management held 6,448 shares of Soleno Therapeutics worth $436K as of Q3 2025.
  • Glenmede Investment Management bought 1,095 Soleno Therapeutics shares in Q3 2025, an estimated $81.2K.
  • Soleno Therapeutics made up ﹤0.01% of Glenmede Investment Management's portfolio in Q3 2025, its #981 holding.
  • Glenmede Investment Management first reported a position in Soleno Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • Glenmede Investment Management's Soleno Therapeutics position peaked at $448K in Q2 2025.
  • 240 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.